Company
.:[TICKER]
We know data. How to collect, analyze, and turn anonymized, aggregated and privacy-compliant data into tangible, actionable decisions. And we are committed to empowering governments and businesses, growing the industry, and inspiring our community to achieve their ambitions
170 stories · page 4 of 9
Orthocell’s CelGro platform forms the basis of a specialised collagen ‘rope’ that could help reconstruct the anterior cruciate ligament, a strong band of tissue linking the thigh and shin bones that can rupture during athletic activity.
The data-backed clinical drug development and care delivery company will leverage the platform to develop its real world evidence asset and accelerate its drug development programs.
A rescheduling decision could help introduce psychedelics to the psychiatrist’s office — and they’ve got off-the-charts potential to treat mental health conditions.
The Therapeutic Goods Administration released an Independent Expert Panel Report reviewing the therapeutic potential of MDMA and psilocybin ahead of the Advisory Committee of Medicines Scheduling at the November 3, 2021 meeting, which may d
As it embarks on the novel MDMA program, the drug development and care delivery company has completed preliminary analysis over half of its MDMA analogue library, developed in conjunction with the University of Western Australia.
“I’m pleased to support Emyria’s unique model of care delivery, evidence generation and treatment development, which is well-placed to evaluate how best to deliver these treatments consistently and safely,” says new appointment.
The regenerative medicine company could be on the verge of developing the first off-the-shelf biological device used to treat ACL injuries, a market linked to a growing health economic burden.
The company’s pre-clinical studies have shown at a microscopic level that CelGro® produces superior nerve repair and return of muscle function in severed peripheral nerves when compared to the traditional (direct suture) repair method.
The results highlight the potential of uniquely designed MDMA-analogues to elicit different neurological effects, which may lead to new treatments for psychiatric and neurological disorders such as PD.
“This is an important development milestone for Ortho-ATI and the company, representing the first randomised controlled trial for a tendon cell therapy to be completed for this indication globally,” says MD.
The regenerative medicine company focused on advancing its CelGro® and Ortho-ATI® pipelines during FY21, ending the period with more than $16 million in the bank.
“This preclinical work will help strengthen Emyria’s intellectual property relating to our synthetic cannabinoid platform. Importantly, this work will help guide the novel formulation, delivery, and dosing strategies of our platform as we p
The week has been highlighted by company reporting, however, one event stood out: the BHP/Woodside merger. The companies announced late on Tuesday that they had entered into an agreement to merge their respective oil and gas portfolios with
The company recently secured exclusive rights to a library of more than 100 novel MDMA analogues from the University of Western Australia, creating a unique drug discovery pipeline for Emyria.
China’s resolve to reduce the impact of the steel industry on the environment is having ramifications for Australia’s mining stocks and iron ore prices. Iron ore was down 1.5% to US$162.96 a tonne overnight and is likely to continue its dec
Emyria is on track to deliver one of the first successfully registered, over-the-counter CBD medicines in Australia and has already completed much of the preliminary registration work.
Emyria has secured exclusive rights to a library of more than 100 novel MDMA analogues from the University of Western Australia creating a unique drug-discovery pipeline.
The findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic grafts and their use in novel surgical treatments for patients suffering from lymphedema.
Emyria advanced its cannabinoid-based drug registration programs and launched an MDMA-assisted therapy trial for people with post-traumatic stress disorder during the June quarter.
The ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting its Striate+ product to the US market over the June quarter, with data from a rotator cuff trial using the Ortho-ATI® product anticipated this
